The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
(Approval lapsed) JEMPERLI dostarlimab 500 mg concentrate for solution for infusion vial (GSK, UK)
Section 19A approved medicine
(Approval lapsed) JEMPERLI dostarlimab 500 mg concentrate for solution for infusion vial (GSK, UK)
Section 19A approval holder
GlaxoSmithKline Australia Pty Ltd ABN 47 100 162 481
Phone
1800 033 109
Approved until
Status
Expired
Medicines in short supply/unavailable
JEMPERLI dostarlimab 500 mg concentrate for solution for infusion 10 mL vial - ARTG 352631
Indication(s)
JEMPERLI is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer.
JEMPERLI is indicated as monotherapy for the treatment of adult patients with recurrent or advanced mismatch repair deficient (dMMR) endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.
Images
